132 related articles for article (PubMed ID: 37078179)
1. Cardiac side effects of propranolol in infants treated for infantile haemangiomas.
Maliqari N; Duka E; Kuneshka L
Cardiol Young; 2023 Dec; 33(12):2616-2620. PubMed ID: 37078179
[TBL] [Abstract][Full Text] [Related]
2. Interventions for infantile haemangiomas of the skin.
Novoa M; Baselga E; Beltran S; Giraldo L; Shahbaz A; Pardo-Hernandez H; Arevalo-Rodriguez I
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD006545. PubMed ID: 29667726
[TBL] [Abstract][Full Text] [Related]
3. Monitoring oral propranolol for infantile hemangiomata.
Bar J; Bar-Ilan E; Cleper R; Sprecher E; Samuelov L; Mashiah J
Dermatol Ther; 2022 Nov; 35(11):e15870. PubMed ID: 36177767
[TBL] [Abstract][Full Text] [Related]
4. Propranolol in infantile haemangioma: simplifying pretreatment monitoring.
El Ezzi O; Hohlfeld J; de Buys Roessingh A
Swiss Med Wkly; 2014 Mar; 144():w13943. PubMed ID: 24610228
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Nagata E; Kashiwagura Y; Okada E; Tanaka S; Sano S; Nishida M; Hayano S; Iwashima S; Hakamata A; Odagiri K; Inui N; Watanabe H; Umemura K; Uchida S
J Pharmacol Sci; 2022 Jun; 149(2):60-65. PubMed ID: 35512856
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of systemic propranolol for severe infantile haemangioma of the orbit and eyelid: a case study of eight patients.
Thoumazet F; Léauté-Labrèze C; Colin J; Mortemousque B
Br J Ophthalmol; 2012 Mar; 96(3):370-4. PubMed ID: 21673014
[TBL] [Abstract][Full Text] [Related]
7. Blood Pressure Monitoring During the Induction and Maintenance Period of Propranolol Therapy for Complicated Infantile Hemangiomas: A Prospective Study of 109 Infants.
Hengst M; Oelert M; Hoeger PH
Pediatr Dermatol; 2015; 32(6):802-7. PubMed ID: 26391729
[TBL] [Abstract][Full Text] [Related]
8. Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice.
Prescrire Int; 2015 Jul; 24(162):173-6. PubMed ID: 26240880
[TBL] [Abstract][Full Text] [Related]
9. Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
Fogel I; Ollech A; Zvulunov A; Valdman-Greenshpon Y; Atar Snir V; Friedland R; Lapidoth M; Ben-Amitai D
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):2004-2009. PubMed ID: 29573481
[TBL] [Abstract][Full Text] [Related]
10. Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children.
Techasatian L; Komwilaisak P; Panombualert S; Uppala R; Jetsrisuparb C
Acta Paediatr; 2016 Jun; 105(6):e257-62. PubMed ID: 26919396
[TBL] [Abstract][Full Text] [Related]
11. Infantile haemangiomas that failed treatment with propranolol: clinical and histopathological features.
Phillips RJ; Lokmic Z; Crock CM; Penington A
J Paediatr Child Health; 2014 Aug; 50(8):619-25. PubMed ID: 24905852
[TBL] [Abstract][Full Text] [Related]
12. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas.
Babiak-Choroszczak L; Giżewska-Kacprzak K; Dawid G; Gawrych E; Bagłaj M
Adv Clin Exp Med; 2019 Mar; 28(3):375-384. PubMed ID: 30659785
[TBL] [Abstract][Full Text] [Related]
13. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol.
Solman L; Murabit A; Gnarra M; Harper JI; Syed SB; Glover M
Arch Dis Child; 2014 Dec; 99(12):1132-6. PubMed ID: 25123404
[TBL] [Abstract][Full Text] [Related]
14. Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
Adams L; Ryan E
Australas J Dermatol; 2022 Nov; 63(4):473-478. PubMed ID: 35938573
[TBL] [Abstract][Full Text] [Related]
15. [Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment].
Csoma ZR; Dalmády S; Ábrahám R; Rózsa T; Rácz K; Kemény L
Orv Hetil; 2017 Oct; 158(39):1535-1544. PubMed ID: 28942665
[TBL] [Abstract][Full Text] [Related]
16. Infantile Periocular Haemangioma: Optimising the Therapeutic Response.
Taylor RH
Paediatr Drugs; 2016 Jun; 18(3):157-60. PubMed ID: 27043724
[TBL] [Abstract][Full Text] [Related]
17. Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Twist J; Chen A; Poffenberger P; Zinn Z
Pediatr Dermatol; 2022 Mar; 39(2):273-274. PubMed ID: 35178766
[TBL] [Abstract][Full Text] [Related]
18. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
Hermans DJ; Bauland CG; Zweegers J; van Beynum IM; van der Vleuten CJ
Br J Dermatol; 2013 Apr; 168(4):837-43. PubMed ID: 23278381
[TBL] [Abstract][Full Text] [Related]
19. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Gatts JE; Rush MC; Check JF; Samelak DM; McLean TW
Pediatr Dermatol; 2022 May; 39(3):389-393. PubMed ID: 35243678
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review.
Diociaiuti A; Carnevale C; Torres EB; Léauté-Labrèze C; Neri I; Rotunno R; Figà-Talamanca L; El Hachem M
Acta Derm Venereol; 2020 Sep; 100(16):adv00255. PubMed ID: 32735025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
